June 30, 2026 a 01:00 pm

BSX: Analysts Ratings - Boston Scientific Corporation

Historical Stock Grades

As of June 2026, the analyst ratings for BSX exhibit a stable positive sentiment, with majority recommendations in the 'Buy' category. The consistent lack of sell-oriented ratings indicates ongoing confidence in the company's future performance despite slight fluctuations in 'Strong Buy' and 'Buy' categories.

Recommendation	Count	Score
Strong Buy	7
Buy	20
Hold	4
Sell	0
Strong Sell	0

Sentiment Development

The sentiment analysis of Boston Scientific Corporation (BSX) indicates a nuanced shift in analyst opinions over several months. While the overall sentiment remains positive, there has been a gradual transition with 'Strong Buy' ratings decreasing slightly, and 'Buy' recommendations showing a small decline:

• Notable decrease in 'Strong Buy' ratings from 10 in March 2026 to 7 in June 2026.
• 'Buy' ratings have decreased from 26 in February 2026 to 20 in June 2026.
• Total recommendation count remains stable, with no 'Sell' or 'Strong Sell' recommendations for an extended period, signifying strong market confidence.

Percentage Trends

Percentage trends reveal a shift in the weight of analyst recommendations. Notably, the decline in 'Strong Buy' recommendations has led to an increased proportion of 'Buy' and 'Hold' ratings.

• In February 2026, 'Strong Buy' accounted for approximately 23.7% of ratings, decreasing to 21.2% by June 2026.
• 'Buy' ratings declined from 68.4% in February to 60.6% in June 2026.
• The most significant shifts occurred between March and June 2026, highlighting a model of cautious optimism among analysts.

Latest Analyst Recommendations

Recent analyst recommendations for BSX show a consensus among leading analysts, primarily maintaining their positions:

Date	New Recommendation	Last Recommendation	Publisher
2026-06-25	Buy	Buy	Stifel
2026-06-24	Buy	Buy	Jefferies
2026-06-16	Buy	Buy	BTIG
2026-06-04	Buy	Buy	Truist Securities
2026-06-03	Buy	Buy	BTIG

Analyst Recommendations with Change of Opinion

Analyst recommendations for BSX have occasionally reflected changes in opinion. While most reviews remained consistent, some noteworthy adjustments depict a moderated viewpoint:

Date	New Recommendation	Last Recommendation	Publisher
2026-05-29	Peer Perform	Outperform	Wolfe Research
2026-05-28	Equal Weight	Overweight	Wells Fargo
2026-03-30	Outperform	Strong Buy	Raymond James
2025-09-08	Outperform	Perform	Oppenheimer
2025-04-16	Buy	Hold	Needham

Interpretation

The market assessment of Boston Scientific Corporation remains largely positive, characterized by a steady confidence in the firm's medical technological advancements. The analysts' sentiment, revealed through consistent 'Buy' and 'Strong Buy' recommendations, confirms the robust belief in the firm's growth potential and market position. The lack of negative evaluations suggests no immediate concerns about market volatility in relation to BSX's activities. However, the marginal decrease in top-tier ratings might indicate cautious optimism or a balanced perspective on upcoming market conditions. Overall, the stability in recommendations depicts an enduring faith within the analyst community.

Conclusion

In conclusion, BSX continues to garner favorable analyst views, reinforcing its reputation for innovation and leadership within the medical tech sector. The company's consistent ratings reflect confidence in sustained growth and the possible expansion of market share. Risks appear minimal, with no sell-side pressure from analysts. However, the slight reduction in 'Strong Buy' ratings advises prudent vigilance on modifying market climates or competitive factors. For analysts, the analysis reaffirms Boston Scientific's standing as a reliable investment but emphasizes the importance of maintaining a vigilant eye on future development trajectories to uphold informed positions.